GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Net Margin %

Palatin Technologies (Palatin Technologies) Net Margin % : -385.64% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Palatin Technologies's Net Income for the three months ended in Dec. 2023 was $-7.84 Mil. Palatin Technologies's Revenue for the three months ended in Dec. 2023 was $2.03 Mil. Therefore, Palatin Technologies's net margin for the quarter that ended in Dec. 2023 was -385.64%.

The historical rank and industry rank for Palatin Technologies's Net Margin % or its related term are showing as below:

PTN' s Net Margin % Range Over the Past 10 Years
Min: -19005.08   Med: -83.11   Max: 17775.66
Current: -445.11


PTN's Net Margin % is ranked worse than
63.88% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs PTN: -445.11

Palatin Technologies Net Margin % Historical Data

The historical data trend for Palatin Technologies's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Net Margin % Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.33 -19,005.08 17,775.66 -2,465.80 -567.41

Palatin Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 263.84 -597.66 -608.06 -279.58 -385.64

Competitive Comparison of Palatin Technologies's Net Margin %

For the Biotechnology subindustry, Palatin Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Net Margin % distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Net Margin % falls into.



Palatin Technologies Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Palatin Technologies's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin=Net Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-27.542/4.854
=-567.41 %

Palatin Technologies's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-7.844/2.034
=-385.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies  (AMEX:PTN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Palatin Technologies Net Margin % Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies (Palatin Technologies) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Executives
Stephen T Wills officer: Executive Vice President, CFO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana director, officer: President and CEO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull director PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff director, officer: Exec. VP Research and Devel. C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104